Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.361,15
-0,42%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Y mAbs Therapeutics Inc (YMAB) Y mAbs Therapeutics Inc (YMAB) Notizie

YMAB

Y mAbs Therapeutics (YMAB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:YMAB
DataOraFonteTitoloSimboloCompagnia
14/06/202403:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
13/06/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:YMABY mAbs Therapeutics Inc
10/06/202422:59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
07/06/202413:05GlobeNewswire Inc.Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
05/06/202413:05GlobeNewswire Inc.Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development OfficerNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202414:15GlobeNewswire Inc.Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202414:05GlobeNewswire Inc.Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
07/05/202422:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:YMABY mAbs Therapeutics Inc
07/05/202422:05GlobeNewswire Inc.Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
26/04/202413:05GlobeNewswire Inc.Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024NASDAQ:YMABY mAbs Therapeutics Inc
25/04/202422:05GlobeNewswire Inc.Y-mAbs to Present at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
14/03/202414:05GlobeNewswire Inc.Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerNASDAQ:YMABY mAbs Therapeutics Inc
04/03/202413:30GlobeNewswire Inc.Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of DirectorsNASDAQ:YMABY mAbs Therapeutics Inc
29/02/202423:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:YMABY mAbs Therapeutics Inc
29/02/202422:05GlobeNewswire Inc.Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
16/02/202413:30GlobeNewswire Inc.Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024NASDAQ:YMABY mAbs Therapeutics Inc
06/02/202421:59Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:YMABY mAbs Therapeutics Inc
02/01/202422:05GlobeNewswire Inc.Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:YMABY mAbs Therapeutics Inc
13/12/202322:05GlobeNewswire Inc.Y-mAbs Therapeutics Added to the NASDAQ Biotechnology IndexNASDAQ:YMABY mAbs Therapeutics Inc
13/11/202322:05GlobeNewswire Inc.Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
08/11/202323:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
31/10/202312:05GlobeNewswire Inc.Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023NASDAQ:YMABY mAbs Therapeutics Inc
18/10/202322:05GlobeNewswire Inc.Y-mAbs Names Michael Rossi as President and Chief Executive Officer and DirectorNASDAQ:YMABY mAbs Therapeutics Inc
18/10/202300:01Dow Jones NewsY-mAbs Therapeutics New Drug Application Gets FDA ClearanceNASDAQ:YMABY mAbs Therapeutics Inc
17/10/202322:05GlobeNewswire Inc.Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADANASDAQ:YMABY mAbs Therapeutics Inc
16/10/202322:05GlobeNewswire Inc.Y-mAbs Announces Publication in CancersNASDAQ:YMABY mAbs Therapeutics Inc
21/09/202322:05GlobeNewswire Inc.Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric OncologyNASDAQ:YMABY mAbs Therapeutics Inc
06/09/202322:05GlobeNewswire Inc.Y-mAbs to Participate at Upcoming Investor Conferences in SeptemberNASDAQ:YMABY mAbs Therapeutics Inc
10/08/202322:05GlobeNewswire Inc.Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
02/08/202322:05GlobeNewswire Inc.Y-mAbs to Participate at Upcoming Investor ConferencesNASDAQ:YMABY mAbs Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:YMAB

La tua Cronologia

LBNK
FILEDOGEUSDT
FILEDOGE
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network